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Stroke is a leading cause of death and long-term disability. This due to the ischemic event that cause by embolism of 
blockage blood flow. Thrombolytic agent plasminogen activator (tPA) is the only treatment approved by FDA. However, 
the used of tPA is limited to the short time window period. Neural stem cells (NSCs) show the potential to repair neuronal 
damage naturally after stroke. However, isolating NSCs is a challenging process due to the limitations of the method and 
its invasiveness. Some studies that had used mesenchymal stem cell (MSCs) as the main source of stem cell for therapy 
show that MSCs have the potency to differentiate into NSCs. in vitro, a differentiation process from MSC to NSC has been 
developed by combining the supplement or growth factor needed in the culture media. 
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Introduction
A stroke, also called a ‘brain attack’, occurs when a clot 
blocks the blood supply to the brain or when a cerebral 
blood vessel bursts, and is a leading cause of serious long-
term disability.1 There are two types of stroke, hemorrhagic 
stroke and ischemic stroke.2,3 Ischemic stroke occurs due to 
cerebral vascular obstruction, thus limiting the blood supply 
containing vital oxygen and substrate to neurons (hypoxia).4 
A small percentage, caused by rupture of the brain's blood 
vessels, is called a hemorrhagic stroke.5
 Stroke kills almost 130,000 of the 800,000 Americans 
who suffer from it each year.6 In Indonesia, stroke is 
the number one killer, with a 15.4% prevalence in the 
population. Ischemic stroke accounted for most of the 
cases (67.1%), while hemorrhagic strokes accounted for the 
remaining 32.9%. Hypertension is the most common risk 
factor for both hemorrhagic (71.2%) and ischemic stroke 
(63.4%).7
 A stroke requires immediate medical attention and 
care because damage to the brain evolves rapidly. In case 
of ischemic stroke, intravenous thrombolytic agents, which 
pharmacologically dissolve clots are used for an acute 
treatment. So far, tissue plasminogen activator (tPA) is the 
only Food and Drug Administration (FDA) approved drug 
for acute ischemic strokes and should be used within 4.5 
hours from the onset of stroke symptoms.2,3
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 Another stroke therapies is needed in order to improve 
outcomes for most of the stroke patients. As there is a 
second therapeutic time window for nerve regeneration 
that appeared days or weeks after stroke.4 Stem cell therapy 
using mesenchymal and neural stem cell shows potential 
as an alternative interventions for modifying disease 
therapy. In this article, we present a brief overview of how 
mesenchymal stem cell could be used directly or to be trans-
differentiate into neural stem cell in in vitro. 
Stem Cell for Therapy 
Over the past decade, the improving field of stem cell 
biology has become a common concern among scientists 
because of its unique properties that potentially offer ideal 
solutions to many health problems, including stroke.8 Stem 
cell therapy has been reported to shown promising result in 
tissue regeneration and homeostasis after an injury.5 Stem 
cell therapy offers the promise of treating diseases and 
playing a role as an alternate source of biological material 
for cell restorative treatments, which currently have no or 
limited therapeutic options.9 Stem cells have the ability to 
develop into many different cell types, with each new cell 
capable of either remaining as a stem cell or differentiating 
into another cell type with a more specific function.8 
 In the process of neuron regeneration, it is beliefs 
that stem cell have two importants role. Stem cell is used 
to replace the dead cells to the injury, such as replacing the 
lost neurons in order for a new neuronal circuitry could be 
rebuild. The others role is through enhancing the exogenous 
stem cells to secrete trophic factors that will support the 
self repair systm of cell in the infarct area. This trophic 
factors could have effect for neuroprotection through anti-
inflammation, antioxidative, antiapoptosis, blood brain 
barrier protection dam promoting the angiogenesis dan 
neurogenesis.10,11 Due to inflamation after stroke event, 
injured cell will secrete tumor necrosis factor-α (TNF-α), 
interleukin (IL)-1, and IL-6, which will increase microglia 
in the brain.12
 There are two main sources of stem cells, namely 
embryonic stem cells (ESC) and adult stem cells (ASC). 
ESCs are cells isolated from the embryonic inner cell 
mass, which is formed in the early stage of embryonic 
development. They are pluripotent, genetically normal 
and able to proliferate extensively in an undifferentiated 
state, therefore they can provide an unlimited source of 
many tissue types.8,13 Human ESCs have great potential to 
differentiate and are able to form cells of all three embryonic 
germ layer lineages.9 The transplantation of pluripotent 
stem cells, including ESCs, to supply new neurons to the 
infarcted brain region of stroke patients is one mechanism 
to decrease ongoing degenerative processes. The cells can 
replace the dead neural tissue in the infarction area. ESCs 
can be prompted to differentiate into neural progenitor cells 
by using several methods. ESC-derived neural cells can 
survive in brain stroke lesioned areas, and then differentiate 
into mature neurons.11,14 
 Other source of stem cells, which are part of a specific 
organ system that only differentiate into appropriate 
phenotypes for tissues in specific organs, are called 
ASCs and are found in post-natal tissues. ASCs display 
significant variation, and sometimes some tissues contain 
more than one type of ASC.8,15 ASCs may be a good choice 
for stroke therapy because they secrete various bioactive 
substances into the infarct area, which may be associated 
with enhancement of neurogenesis and angiogenesis.11,15 
Mesenchymal stem cells (MSCs) are one type of ASCs that 
have been used for most clinical trials, which suggest they 
may have good potential in stroke therapy.16 
Mesenchymal Stem Cell
MSCs are a multipotent type of self-renewing cells that 
produce different daughter cells when implanted into the 
appropriate tissue network.16 MSCs can be isolated from 
bone marrow, umbilical cord and adipose tissue, and they 
express the specific mesenchymal markers CD105, CD90, 
and CD73.17,18 The other characteristics of MSCs is the 
ability to differentiate into osteocytes, chondrocytes, and 
adipocytes.17 MSCs secrete various bioactive substances, 
including trophic factors and extracellular vesicles into the 
brain lesion15, to enhance neurogenesis, angiogenesis, and 
synaptogenesis. In addition, MSCs play a role in reducing 
inflammation, reducing scarring, normalizing the micro/
metabolic environment profiles, and possibly replacing 
damaged cells in various brain diseases.4,15,16,19 Thus, MSCs 
have great potential in the treatment of stroke. In addition, 
MSCs are generally derived from autologous tissue, which is 
precluded from ethical controversy surrounding stem cells. 
MSCs are easily cultured in vitro, has weak immunogenicity 
(because it expresses few HLA class I and no HLA class 
II molecules) and allows for good safety. Thus, MSCs are 
safely suggested as an ideal seed cell in the treatment of 
ischemic stroke.4,17
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Mechanisms of Action for MSC
MSCs contribute to the treatment of cerebral ischemia 
through multiple mechanisms, such as cell migration20, 
angiogenesis, prevention of apoptosis, increased 
proliferation, neurotrophic factor secretion, neural circuit 
reconstruction and immunomodulation. They also reduce 
scar formation by reducing reactive glycogenesis.21,22 In 
particular, MSCs provide a neuroprotective effect through 
cell migration to the infarct region, where they subsequently 
secrete neurotrophic factors.21 These neurotrophic factors 
will then activate endogenous cellular repair programs in 
the infarct region.3
 MSCs exhibit the feature for homing and repair 
the injured nerve tissue is because its ability to migrate 
and survive in the ischemic hemisphere, creating a 
microenvironment conducive for cell survival and 
regeneration.4,23 MSCs migration into the infarct area 
is through the stromal cell-derived factor-1 (SDF-1)/C-
X-C chemokine receptor (CXCR)-4 signalling pathway. 
The pathway serve as the homing signal for MSCs.24 
SDF1/C-X-C motif chemokine ligand (CXCL)-12 is a 
small molecule which belong to CXC chemokine family.25 
Hypoxia-responsive transcription factor hypoxia inducible 
factor 1 (HIF-1) will induce microglia and astrocytes to 
secrete SDF-1 in the infarct area after stroke.23 SDF-1 will 
interact with CXCR-4, the physiological receptor for SDF-
1, expressed by MSCs on the cell surface and inside it.The 
SDF-1/CXCR-4 interaction causes the MSCs migration 
into the infarct area.21 This mechanism involves in the 
process of tissue repair in both exogenous and endogenous 
fashions.22 due to the activation of CXCR-4 which triggered 
multiple signals for cell survival, chemotaxis, proliferation, 
apoptosis, and differentiation.25
 in vitro studies have shown that MSCs secrete at 
several types of trophic factors after co-culturing with 
cortical neurons under hypoxic conditions. Some of the 
tropic factor of MSCs have neuroprotective effect in the 
early stages of transplantation and also induce parenchymal 
cells in host tissue.4,17,26 These neurotrophic factors trigger 
functional recovery after stroke through decreased apoptosis 
and inflammation as well as an endogenous proliferation 
of stem cells and progenitor cells in peri-infarcted tissues, 
angiogenesis, and neurogenesis.21 This neurotrophic factors 
has a target to activate the endogenous repair of neuro-
progenitor cells (NPS) in the subventricular zone (SVZ).3 
Neutrophic factor produce by MSC includes brain-derived 
neurotrophic factor (BDNF), fibroblast growth factor 
(FGF)-2, glial cell-derived neurotrophic factor (GDNF), 
neurotrophin (NT)-3 an other that are listed in Table 1 with 
their fuctions.
 During the process of neuron repair in ischemic stroke, 
microglia will activate and produce pro-inflammatory 
cytokines. This is a microglia 1 (M1) phenotype mechanism 
associated with tissue destruction. MSCs will secreted 
paracrine factors to inhibit the activity of M1 phenotype 
microglia and induce the activation of the microglia 2 (M2) 
phenotype which is the anti-inflammatory phenotype.12











B Transforming growth factor β  (TGF-β) Anti-apoptotic




Stem Cell and 
Progenitor Cell Support
Secretion of stem cell factor (SCF) Stem Cell and 
Progenitor Cell Support
Interleukin-6 (IL-6) Angiogenesis
Basic fibroblast growth factor (bFGF) Angiogenesis
Granulocyte macrophage colony stimulation 
factor (GM-CSF)
Anti-apoptotic
Basic fibroblast growth factor (bFGF)
Hepatocyte growth factor (HGF)
Insulin-like growth factor 1 (IGF-1)
Vascular endothelial growth factor (VEGF)
Neural Stem Cell
Neural Stem Cell (NSCs) are multipotent stem cells of 
the central nervous system (CNS)29, particularly in the 
brain’s SVZ  and the sub-granular zone (SGZ).28  It has 
three features as stem cells: the ability to self-renew, to 
differentiate into neural lineage cells, and to regenerate 
neural tissue. These neural lineages are neurons, astrocytes, 
and  oligodendrocytes.30 When differentiating, NSCs commit 
to specific lineage, from progenitor cells into neuronal and 
glial cells.31 To characterize the cells, cell markers can be 
used  for  identification.  The  NSC  antibody  markers  and 
the lineage restricted precursor are listed in Table 2.
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Table 2. Antibody markers used for NSC immunophenotyping.30
Glial Reference Neurons Reference
Integrin α1β5 (32) A2B5 (33–36) PSA-NCAM (35,37)
CD15 (37–39) CD44 (40) βIII-tubulin (41)
CD24 (42,43) CD3 (33) MAP-2 (41)
CD133 (37,39,44) NG2 (45) Doublecortin (41)
CXCR4 (39) O1 (46)








CD: cluster of differentiation; CXCR: C-X-C chemokine receptor; NOTCH1: Notch 
homolog 1; EGF: epidermal growth factor; EGFR1: EGF receptor-1; NG2: neural/
glial antigen 2; GFAP: glial fibrillary acidic protein;  Gal-c: galactocerebroside; 
MBP: myelin basic protein; PSA-NCAM: polysialylated neural cell adhesion 
molecule; MAP-2: Microtubule-associated protein-2.
 Recent studies of NSCs show that NSCs have potential 
for future cell therapy. Protocols has been developed to 
isolate and expand NSCs in vitro, but are difficult to manage 
due to resource constraints.30 Further studies on expanding 
NSCs  are  needed  in  producing cells  for therapy.
Mechanism of NSC 
Repairing the brain after stroke using the MSCs had 
been done  and  some  cases  had  been  reported  in  the 
clinicaltrials.gov database. However, these are also reports 
that the potency of MSCs for neural repair may be limited 
in patients who have limited numbers of NSCs.11 In an 
ischemic stroke injury, the SVZ niche will be activated so 
that the proliferation of NSCs will increase to accommodate 
the injury. The new cells will migrate and differentiate into 
lineage-specific cell types.14 NSCs are able to differentiate 
into mature neurons to be integrated into neural circuits to 
recover the lost function.28 
 The repair mechanism involves the integration of cells 
into the lesion site. NSCs will produce neuroblasts within 
three days of the stroke.28 Neuroblasts from the rostral 
migratory stream (RMS) will migrate to the olfactory 
bulb. The neuroblasts will then migrate from the SVZ by 
a hemophilic mechanism and a vasophilic mechanism 
(using blood vessels) for locomotion. Migration from RMS 
is controlled by chemo-repulsion factors Slit1 and Slit2, 
and by chemo-attraction factors such as netrin, neuregulin, 
ephrin, and BDNF. Deficiency of polysialyated neural cell 
adhesion molecules (PSA-NCAM) and b1-integrins will 
result in a decrease in NSC migration.29 
 Differentiation of NSCs will produce neurons, 
astrocytes and oligodendrocytes. However, only, 20% of 
dead tissue will be replaced. The 80% of the newly formed 
neurons will die.28 This is because the microenvironment in 
ischemic strokes is unsuitable for the survival of endogenous 
NSC-derived neurons and often, cells will differentiate into 
glia.50 In order for NSCs to perform effective repair, they 
induce a neuro-inflammatory response to activate astrocytes, 
microglia and angiogenesis by releasing chemokines 
and growth factors such as CXCL12, erythropoietin, 
mitochondrial pyruvate carrier (MPC)-1, angiopoietin-1, 
BDNF, GDNF, and vascular endothelial growth factor 
(VEGF).28 The BDNF, nerve growth factor (NGF), GDNF 
and ciliary neurotrophic factor (CNTF) are responsible for 
prevention of neuronal apoptosis and formation of glial 
scars.50
Approach for MSC Transdifferentiation to NSC 
in vitro and in vivo studies have shown that MSCs have 
the capability to transform into neural lineage cells, 
including neurons, glia, and Schwann cells51, and also into 
vascular endothelial cells.22 This ability is classified as 
trans-differentiation, which describes the ability to change 
between committed cell lineage of differentiation. in vitro 
differentiation of MSCs is done by adding stimulants52, 
such as growth factors into the culture media.51 Growth 
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factors such as epidermal growth factor (EGF), basic 
fibroblast growth factor (bFGF)54, NGF, interferon-g, and 
chemical agents, such as retinoic acid (RA)53, dimethyl-
sulfoxide (DMSO), and β-mercaptoethanol (BME) could 
induce the differentiation of MSCs into NSCs.31 Forskolin 
and 3-isobutyl-1-methylxanthine (IBMX), platelet derived 
growth factor homodiner B (PDGF-BB), heregulin B27, 
could also induce the differentiation of MSCs into NSCs.54,55
 Woodbury, et al., reported that using chemical agents 
shows that after several hours nearly 80% of the MSCs 
turned into neuronal morphology cells. These cells were 
confirmed using immunofluorescence staining with nestin 
after 5 hours of treatment.56 Nestin is an intermediate 
filament protein expressed in neuroepithelial neuronal 
precursor stem cells. The expression of nestin will decrease 
with neuronal maturation. Other markers such as TrkA, Tau, 
neuron-specific enolase (NSE), glial fibrillary acidic protein 
(GFAP), neuron-specific nuclear protein (NeuN) are also 
used to confirm these neural lineage cells.53,56,57
Stem Cell Therapy for Stroke Using MSC and 
NSC
Stem cell transplantation for stroke had been performed 
more than 15 years ago. However, to date, there is no optimal 
model yet. Early studies of stem cell therapy for treating 
strokes were based on replacing neural cells that were lost as 
a result of ischemic brain injury. These cells can be neuronal, 
astrocytic, oligodendroglial, or endothelial in phenotype.58 
The success of stem cell therapy is influenced by the type of 
stem cell, cell doses, and route of administration.3 
 Many publications has been reported the used of 
MSCs in stroke therapy. Paracrine effect is believed to 
be the most important mechanism in improvement of 
neurological function. This include the action of enchancing 
the angiogenesis and neurogenesis as an immunomodulation 
and anti-inflamation molecule. The paracrine effect will 
activate because of the infiltation of neutrophils and 
macrophages in blood brain barrier.1 However, some paper 
also reported that intravenous administration of MSC show 
no improvement in stroke patient.19,22 This might due to the 
limited number of NSCs to replace the injured neurons. 
 Administration of MSCs and MSC-derived-NSCs 
could be a new approach to treat neurological disorder such 
as stroke.59 Both stem cells will have different mechanism 
to in the treatment. MSC-derived-NSCs will serves as the 
exogenous NSC to replace the injured neurons. Evidence 
also suggesting that NSCs secrete neurotrophic factors that 
protect dysfunctional motor neurons. Other neurotropic 
factor such as NGF and neurotrophin-3, GDNF, and bovine 
dermal fibroblasts (BDF) will increase the survival of 
dopaminergic neurons, therefore the neurons will survive 
and new neurons and synapses will grow.60
Conclusion
Stem cell therapy for repairing the nervous system after an 
ischemic stroke has been conducted several years ago. NSCs 
will replace the dead cell after stroke, however it is not easy 
to to isolate NSC due to invasive procedure. We hope that 
the in vitro MSC trans-differentiated NSC could be used 
as an alternative for external source of cell in regenerative 
therapy.  
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